Estrella Immunopharma, Inc.

ESLA Nasdaq CIK: 0001844417

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
Business Address 5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
Mailing Address 5858 HORTON STREET, SUITE 370, EMERYVILLE, CA, 94608
Phone (510) 318-9098
Fiscal Year End 1231
EIN 861314502

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 18, 2026 View on SEC
S-1/A IPO registration amendment January 22, 2026 View on SEC
S-1/A IPO registration amendment January 16, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
424B5 Prospectus supplement January 6, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
S-1 IPO registration statement December 22, 2025 View on SEC
8-K Current report of material events December 4, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC
8-K Current report of material events November 6, 2025 View on SEC

Annual Reports

10-K March 18, 2026
  • Lead product candidate EB103 showed promising Phase I results with 100% complete response in high-dose group and no serious treatment-related side effects.
  • The STARLIGHT-1 clinical trial for EB103 was approved to advance to Phase II by an independent Data Safety Monitoring Board (DSMB).
View Analysis

Material Events

8-K Legal Issue January 13, 2026
High Impact
  • The company has 45 calendar days to submit a compliance plan to Nasdaq.
  • Estrella Immunopharma plans to hold its annual shareholder meeting in April 2026.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.